Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Wuxi Biologics Cayman Inc    2269   KYG970081090

WUXI BIOLOGICS CAYMAN INC (2269)
My previous session
Most popular
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Wuxi Biologics Cayman : CANbridge Pharmaceuticals expands partnership with Wuxi Biologics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:40am EST

Chinas CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and commercialisation of four additional drug candidates to potentially treat rare genetic chronic diseases.

As per the agreement, CANbridge holds exclusive regional or global rights to these drug candidates. In turn, WuXi Biologics will receive upfront and milestone payments as well as royalties.

WuXi Biologics will act as the exclusive clinical and primary commercial supplier for all the programmes.

CANbridge Pharmaceuticals founder, chairman and CEO James Xue said: With this expansion of our partnership with WuXi Biologics, CANbridge continues to broaden our presence in rare disease, with a goal of bringing to the market treatments that are developed in China.

These four new drug candidates target important rare disease indications for which there are either no available treatments in China or treatments with poor outcomes.

These candidates are next-generation therapies directed at medically-validated biological targets.

CANbridge and WuXi Biologics initially partnered in October last year to develop and commercialise a range of biotherapeutics targeting rare diseases.

The partnership combines CANbridges clinical, regulatory and commercial expertise with WuXis drug discovery, development and manufacturing capabilities.

First investigational New Drug (IND) application for the lead rare disease candidate from this programme is expected to be submitted later this year in China.

In the future, the partners also intend to develop the therapeutics on a global basis.

WuXi Biologics CEO Chris Chen added: This expanding partnership further validates our world-class technology platforms and capabilities.

Improving the availability of biologics for rare disease aligns with our mission of accelerating and transforming how biologics are developed and manufactured worldwide.

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WUXI BIOLOGICS CAYMAN INC
01/12WUXI BIOLOGICS CAYMAN : CANbridge Pharmaceuticals expands partnership with Wuxi ..
AQ
2018WUXI BIOLOGICS CAYMAN : AC Immune and WuXi Biologics to Establish an Exclusive S..
AQ
2018WUXI BIOLOGICS CAYMAN : Congratulates Tychan on First-in-Class Monoclonal Antibo..
AQ
2018WUXI BIOLOGICS CAYMAN : Oxford BioTherapeutics to develop bispecifics using WuXi..
AQ
2018WUXI BIOLOGICS CAYMAN : Announced Exclusive Discovery Research with Brii Bioscie..
AQ
2018WUXI BIOLOGICS : Announced Exclusive Discovery Research with Brii Biosciences fo..
PR
2018WUXI BIOLOGICS CAYMAN : Tychan begins Phase I Trials for first ever yellow fever..
AQ
2018WUXI BIOLOGICS CAYMAN : Brii expands in infectious via deals with Vir, VBI, WuXi..
AQ
2018WUXI BIOLOGICS CAYMAN : and ABL Bio enter exclusive partnership
AQ
2018WUXI BIOLOGICS CAYMAN : and ABL Bio Enter an Exclusive Development and Clinical ..
AQ
More news
Financials (HKD)
Sales 2018 2 863 M
EBIT 2018 728 M
Net income 2018 646 M
Finance 2018 3 164 M
Yield 2018 -
P/E ratio 2018 111,38
P/E ratio 2019 66,72
EV / Sales 2018 24,0x
EV / Sales 2019 16,0x
Capitalization 71 844 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 83,7  HKD
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ge Li Non-Executive Chairman
Shao Hua Lu-Wong Chief Financial Officer
Weichang Zhou Executive Director, Chief Technology Officer & SVP
Edward Hu Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI BIOLOGICS CAYMAN INC9 159
BIOGEN10.34%66 898
CSL LIMITED6.55%64 342
ALEXION PHARMACEUTICALS14.73%24 920
BIOMARIN PHARMACEUTICAL11.49%17 042
GRIFOLS5.68%16 763